Revitalizing and Rebuilding the Amino-Acid Business and Maintaining and Expanding Top Market Share Through Global Expansion
First written in FY2017. 16 of 33 entries say "Advanced", first in FY2019-Q1. Latest entry: 2026-07-31.
The whole theme swung hardest in 2024: 2 of 8 companies on the "Worse" side.
6 other companies' latest entry also says "Advanced".
- 2026-07-31AdvancedFinancial results
「Because exports of amino acids increased, sales were ¥1,499 million, an increase of ¥293 million, or 24.3%, from the same quarter of the previous year.」
Amino acid-related sales increased 24.3% year on year, showing quantitative progress driven by higher export sales. - FY2026ReframedAnnual report
「・Strengthening the global supply system and increasing value added in the amino-acid field」
For the amino-acid business, the previous goals of revitalization and restructuring and maintaining and expanding the leading market share were reorganized under the new medium-term plan as measures to strengthen the global supply system and increase value added. Sales for the current period were ¥5,156 million, essentially unchanged from the same period of the previous year. - 2026-05-19AdvancedManagement plan
「③ Strengthening the global supply system and creating higher value in the amino acid business」
For the amino acid business, the company identified effective use of existing facilities, construction of a resilient supply chain, maintenance and expansion of its leading share in high-quality markets, and a shift toward a more profitable business structure as priority measures under the new medium-term plan. - FY2026-H1Amino-acid business sales and sales mix declined in the interim periodAnnual report
「Although export sales for pharmaceutical applications were strong, sales for industrial applications declined, resulting in sales of ¥2,435 million, a decrease of ¥229 million, or 8.6%, from the previous interim accounting period.」
Interim-period sales related to amino acids decreased 8.6% from ¥2,665 million in the same period of the previous year to ¥2,435 million, while the sales mix declined from 37.0% to 31.2%. Export sales for pharmaceutical applications were strong, but lower sales for industrial applications weighed on overall results. No change is indicated in the policy of revitalizing and restructuring the amino-acid business or maintaining and expanding the leading market share through global expansion. - FY2025-H1AdvancedAnnual report
「Although export sales for food applications declined, strong sales for semiconductor-related and pharmaceutical applications resulted in sales of ¥2,665 million, an increase of ¥497 million, or 23.0%, from the previous interim accounting period.」
Interim-period sales related to amino acids increased 23.0% from ¥2,167 million in the same period of the previous year to ¥2,665 million. Strong sales for semiconductor-related and pharmaceutical applications contributed to the increase, but no evidence of a leading market share itself is provided. - FY2024ReframedAnnual report
「“Key Measures under the New Medium-Term Management Plan” ・Business structure reform in the amino-acid field」
For the amino-acid business, the previous goals of revitalization and restructuring and maintaining and expanding the leading market share through global expansion were reorganized under the new medium-term plan as the key measure of “business structure reform.” Sales related to amino acids for the current period were ¥4,237 million, down 15.5% from the same period of the previous year. - FY2024-Q3Nine-month cumulative results: lower amino acid-related sales and composition ratioAnnual report
「Although export sales for food applications were strong, sales for semiconductor-related applications declined, resulting in sales of ¥3,076 million, a decrease of ¥595 million, or 16.2%, from the same quarter of the previous year.」
Cumulative third-quarter sales related to amino acids decreased 16.2% from ¥3,671 million in the same period of the previous year to ¥3,076 million, while the sales mix declined from 40.7% to 34.5%. Export sales for food applications were strong, but lower sales for semiconductor-related applications weighed on overall results. No change is indicated in the key measures themselves. - FY2024-Q2Six-month cumulative results: lower amino acid-related sales and composition ratioAnnual report
「Although export sales for food applications were strong, sales for semiconductor-related applications declined, resulting in sales of ¥2,167 million, a decrease of ¥361 million, or 14.3%, from the same quarter of the previous year.」
Cumulative second-quarter sales related to amino acids decreased 14.3% from ¥2,529 million in the same period of the previous year to ¥2,167 million, while the sales mix declined from 40.1% to 37.4%. Export sales for food applications were strong, but lower sales for semiconductor-related applications weighed on overall results. - FY2024-Q1First-quarter results: lower amino acid-related salesAnnual report
「Although sales for pharmaceutical and industrial applications were strong, sales for food and supplement applications declined, resulting in sales of ¥1,155 million, a decrease of ¥42 million, or 3.6%, from the same quarter of the previous year.」
No change is indicated in the key measures themselves, namely the revitalization and restructuring of the amino-acid business and the maintenance and expansion of its leading market share through global expansion. Meanwhile, first-quarter sales decreased 3.6% from ¥1,198 million in the same period of the previous year to ¥1,155 million. - FY2023-Q3AdvancedAnnual report
「Strong sales for pharmaceutical and industrial applications resulted in sales of ¥3,671 million, an increase of ¥422 million, or 13.0%, from the same period of the previous year.」
Cumulative third-quarter sales related to amino acids increased 13.0% from ¥3,249 million in the same period of the previous year to ¥3,671 million. This indicates progress in sales driven by strong sales for pharmaceutical and industrial applications. - FY2023-Q2AdvancedAnnual report
「Strong export sales for supplement, industrial and pharmaceutical applications resulted in sales of ¥2,529 million, an increase of ¥482 million, or 23.6%, from the same quarter of the previous year.」
Cumulative second-quarter sales related to amino acids increased 23.6% from ¥2,046 million in the same period of the previous year to ¥2,529 million. Strong export sales for supplement, industrial and pharmaceutical applications indicate progress in amino-acid business sales. - FY2023-Q1AdvancedAnnual report
「Strong sales for pharmaceutical and food and supplement applications resulted in sales of ¥1,198 million, an increase of ¥231 million, or 24.0%, from the same quarter of the previous year.」
First-quarter sales related to amino acids increased 24.0% from ¥966 million in the same period of the previous year to ¥1,198 million, indicating progress driven by strong sales for pharmaceutical and food and supplement applications. - FY2022AdvancedAnnual report
「Strong export sales of pharmaceuticals, supplements and industrial applications resulted in sales of ¥4,411 million, an increase of ¥573 million, or 14.9%, from the previous fiscal year.」
Full-year sales related to amino acids increased 14.9% from ¥3,838 million in the previous fiscal year to ¥4,411 million. Strong export sales of pharmaceuticals, supplements and industrial applications contributed to the increase. - FY2022-Q3AdvancedAnnual report
「Strong export sales for pharmaceutical, industrial and supplement applications resulted in sales of ¥3,249 million, an increase of ¥319 million, or 10.9%, from the same quarter of the previous year.」
Cumulative third-quarter sales related to amino acids increased 10.9% from ¥2,929 million in the same period of the previous year to ¥3,249 million. This indicates progress driven by strong export sales for pharmaceutical, industrial and supplement applications. - FY2022-Q2AdvancedAnnual report
「Although food exports declined, strong exports for industrial and supplement applications resulted in net sales of ¥2,046 million, up ¥54 million, or 2.8%, from the same quarter of the previous year.」
Cumulative second-quarter sales related to amino acids increased 2.8% from ¥1,991 million in the same period of the previous year to ¥2,046 million, while the sales mix rose from 36.7% to 39.3%. This indicates progress in sales, driven by strong exports for industrial and supplement applications, among others. - FY2022-Q1First-quarter results: lower amino acid-related sales and composition ratioAnnual report
「Although pharmaceutical exports performed well, sales of exports for food and supplements declined, resulting in net sales of ¥966 million, down ¥40 million, or 4.0%, from the same quarter of the previous year.」
Amino acid-related sales decreased 4.0% from ¥1,007 million in the same period of the previous year to ¥966 million, while the composition ratio fell from 38.9% to 37.6%. Pharmaceutical exports performed well, but the decline in food and supplement exports had an adverse impact. - FY2021AdvancedAnnual report
「Although domestic sales for pharmaceutical and food and supplement applications declined, exports for industrial and food and supplement applications increased substantially. As a result, net sales were ¥3,838 million, up ¥353 million, or 10.1%, from the previous period.」
Full-year amino acid-related sales increased 10.1% from ¥3,485 million to ¥3,838 million. The increase in exports for industrial and food and supplement applications indicates progress, but no achievement relating to the leading market share was stated. - FY2021-Q3AdvancedAnnual report
「Although domestic sales declined for pharmaceutical, food and supplement, and industrial applications, sales increased because demand for semiconductor-related products within the industrial applications category rose and exports performed well, among other factors. Net sales were ¥2,929 million, up ¥433 million, or 17.4%, from the same quarter of the previous year.」
Nine-month cumulative amino acid-related sales increased 17.4% from ¥2,496 million in the same period of the previous year to ¥2,929 million, while the composition ratio rose from 31.2% to 39.5%. Strong exports of industrial products related to semiconductors indicate progress in sales, but no reference was made to the leading market share itself. - FY2021-Q2AdvancedAnnual report
「Although domestic sales for pharmaceutical and food and supplement applications declined slightly, exports for food and supplement and industrial applications grew substantially. As a result, net sales were ¥1,991 million, up ¥263 million, or 15.2%, from the same period of the previous year.」
Six-month cumulative amino acid-related sales increased 15.2% from ¥1,728 million in the same period of the previous year to ¥1,991 million, while the composition ratio rose from 32.5% to 36.7%. The increase in exports for food and supplement and industrial applications indicates progress in sales. - FY2021-Q1AdvancedAnnual report
「Although domestic pharmaceutical sales declined, industrial sales related to semiconductors continued to perform well and exports for food and supplements grew substantially. As a result, net sales were ¥1,007 million, up ¥111 million, or 12.5%, from the same quarter of the previous year.」
First-quarter amino acid-related sales increased 12.5% from ¥895 million in the same period of the previous year to ¥1,007 million, while the composition ratio rose from 34.7% to 38.9%. The growth in industrial sales related to semiconductors and exports for food and supplements indicates progress in sales, but no reference was made to the leading market share itself. - FY2020Full-year results: lower amino acid-related salesAnnual report
「Although sales of amino acids declined for some applications, both domestic and export sales increased overall from the previous period. However, domestic and export sales of vitamin raw materials decreased from the strong levels recorded in the previous period, resulting in net sales of ¥3,485 million, down ¥61 million, or 1.7%, from the previous period.」
The policy of revitalizing and rebuilding the amino acid business and maintaining and expanding its leading share of the global market remains in place, but full-year sales decreased 1.7% from the previous period. - FY2020-Q3Nine-month cumulative results: lower amino acid-related sales and composition ratioAnnual report
「In addition to lower amino acid sales, mainly for export, sales of vitamin raw materials declined slightly from the same quarter of the previous year, when both domestic and export sales were strong. As a result, net sales were ¥2,496 million, down ¥37 million, or 1.5%, from the same quarter of the previous year.」
Nine-month cumulative amino acid-related sales decreased 1.5% from ¥2,533 million in the same period of the previous year to ¥2,496 million, while the composition ratio fell from 35.4% to 31.2%. No change was stated in the key initiative of revitalizing and rebuilding the amino acid business and maintaining and expanding its leading market share. - FY2020-Q2Six-month cumulative results: lower amino acid-related sales and composition ratioAnnual report
「Amino acid sales, mainly for export, declined slightly. In addition, export sales of vitamin raw materials fell substantially from the strong level recorded in the same quarter of the previous year, resulting in net sales of ¥1,728 million, down ¥142 million, or 7.6%, from the same quarter of the previous year.」
Six-month cumulative amino acid-related sales decreased 7.6% from ¥1,870 million in the same period of the previous year to ¥1,728 million, while the composition ratio fell from 39.8% to 32.5%. No change was stated in the key initiative. - FY2020-Q1First-quarter results: lower amino acid-related sales and composition ratioAnnual report
「Amino acid sales, mainly for export, were sluggish, resulting in net sales of ¥895 million, down ¥102 million, or 10.3%, from the same quarter of the previous year.」
First-quarter amino acid-related sales decreased 10.3% from ¥998 million in the same period of the previous year to ¥895 million, while the composition ratio fell from 44.6% to 34.7%. No change was stated in the key initiative of revitalizing and rebuilding the amino acid business and maintaining and expanding its leading market share. - FY2019AdvancedAnnual report
「Although amino acid sales, mainly for export, declined, a substantial increase in export sales of vitamin raw materials resulted in net sales of ¥3,546 million, up ¥30 million, or 0.9%, from the same period of the previous year.」
Full-year amino acid-related sales were ¥3,546 million, up 0.9% from the previous period. Although amino acid sales themselves declined, higher exports of vitamin raw materials lifted overall sales. - FY2019-Q3Nine-month cumulative results: lower amino acid-related sales and composition ratioAnnual report
「Although sales of vitamin raw materials increased, amino acid sales, mainly for export, declined. As a result, net sales were ¥2,533 million, down ¥113 million, or 4.3%, from the same quarter of the previous year.」
Nine-month cumulative amino acid-related sales decreased 4.3% from ¥2,647 million in the same period of the previous year to ¥2,533 million, while the composition ratio fell from 35.7% to 35.4%. No change was stated in the key initiative of revitalizing and rebuilding the amino acid business and maintaining and expanding its leading market share. - FY2019-Q2AdvancedAnnual report
「Although amino acid exports declined, higher exports of vitamin raw materials resulted in net sales of ¥1,870 million, up ¥87 million, or 4.9%, from the same quarter of the previous year.」
Six-month cumulative amino acid-related sales increased 4.9% from ¥1,783 million in the same period of the previous year to ¥1,870 million, while the composition ratio rose from 35.2% to 39.8%. The increase in sales indicates progress in revitalizing and rebuilding the amino acid business, but no reference was made to maintaining or expanding the leading market share or to market share itself. - FY2019-Q1AdvancedAnnual report
「Strong amino acid sales, mainly for export, resulted in net sales of ¥998 million, up ¥169 million, or 20.4%, from the same period of the previous year.」
First-quarter amino acid-related sales increased 20.4% from ¥828 million in the same period of the previous year to ¥998 million, while the composition ratio rose from 33.1% to 44.6%. The increase in sales indicates progress in revitalizing and rebuilding the amino acid business, but no reference was made to maintaining or expanding the leading market share or to market share itself. - FY2018Full-year results: lower amino acid-related salesAnnual report
「Net sales decreased to ¥3,516 million, down ¥110 million, or 3.0%, from the same period of the previous year, due to lower sales of vitamin raw materials.」
The key initiative of revitalizing and rebuilding the amino acid business and maintaining and expanding its leading market share remains in place, but full-year amino acid-related sales decreased 3.0% year on year. - FY2018-Q3Nine-month cumulative results: lower amino acid-related sales and composition ratioAnnual report
「Amino acid-related 909 1,864 2,774 37.1 853 1,793 2,647 35.7」
Nine-month cumulative amino acid-related sales decreased from ¥2,774 million in the same period of the previous year to ¥2,647 million, while the composition ratio fell from 37.1% to 35.7%. No change was stated in the key initiative of revitalizing and rebuilding the amino acid business and maintaining and expanding its leading market share. - FY2018-Q2Second-quarter cumulative results: lower amino acid-related sales and composition ratioAnnual report
「Amino acid-related 595 1,216 1,812 37.2 535 1,247 1,783 35.2」
Amino acid-related sales for the six months ended decreased from ¥1,812 million in the same period of the previous year to ¥1,783 million, while the composition ratio fell from 37.2% to 35.2%. No change was stated in the key initiative of revitalizing and rebuilding the amino acid business and maintaining and expanding its leading market share. - FY2018-Q1First-quarter results: lower amino acid-related salesAnnual report
「Amino acid-related 291 653 944 39.8 271 557 828 33.1」
First-quarter amino acid-related sales decreased from ¥944 million in the same period of the previous year to ¥828 million, while the composition ratio fell from 39.8% to 33.1%. No market-share figure was provided in relation to the goal of maintaining and expanding the leading market share. - FY2017First statedAnnual report
「To help create a new healthcare society, the company established a 3-year medium-term management plan beginning with the fiscal year ending March 2017 and covering fiscal 2016 through fiscal 2018. The plan identifies as a key initiative the revitalization and rebuilding of the amino acid business and the maintenance and expansion of its leading market share through global expansion, and the company is implementing these measures.」
The company explicitly identified for the first time the key initiative of revitalizing and rebuilding the amino acid business and maintaining and expanding its leading market share through global expansion.